Relation announced two multi-program strategic collaborations with GSK (GSK). The collaborations will focus on the identification and validation of novel therapeutic targets for fibrotic diseases and osteoarthritis. Under the terms of both agreements, Relation will receive a total upfront payment from GSK of $45 million which comprises an equity investment of $15 million. In addition, Relation will be eligible to receive success-based collaboration payments of up to $63 million, as well as potential preclinical, development, commercial, and sales milestone payments averaging $200 million per target across both deals, along with tiered royalties on net sales of products.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK says median overall survival not reached in multiple myeloma study
- GSK announces NMPA of China accepted review of NDA for Blenrep
- GSK announces U.S. FDA accepted its submission for use of Nucala in COPD
- GSK, Zhifei revise, extend strategic vaccine collaboration in China
- GSK price target lowered to 1,600 GBp from 1,820 GBp at Berenberg